Euglycemic diabetic ketoacidosis associated with ST segment elevation myocardial infarction following SGLT-2 inhibitor therapy - 03/08/23
, Aziz İnan Çelik, MD, Tahir Bezgin, MD, Metin Çağdaş, MDAbstract |
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the latest approved class of oral antidiabetic agents that inhibit renal SGLT-2 receptors and increase urinary glucose excretion in the luminal membrane of the proximal tubule. Diabetic ketoacidosis (DKA) is a triad of hyperglycemia, ketosis, and a high anion gap with metabolic acidosis. We present the case of 61 years-old men with severe euglycemic DKA (EDKA) complicated ST-segment elevation myocardial infarction following SGLT-2 inhibitor therapy for type 2 diabetes mellitus. Atypical presentation of ketoacidosis without hyperglycemia can delay diagnosis and may result in catastrophic complications. Quick diagnosis, appropriate clinical and biochemical assessment, and effective treatment protocols ensure successful resolution of EDKA.
Le texte complet de cet article est disponible en PDF.Keywords : Myocardial infarction, Diabetic ketoacidosis, Euglycemia, Sodium-glucose cotransporter-2 inhibitors
Plan
Vol 71
P. 250.e1-250.e3 - septembre 2023 Retour au numéro
Article précédent
- A case of spinal epidural lipomatosis presenting as a stroke mimic
- Jonas Salna IV, James Lee, Eric Maddock, James Espinosa, Alan Lucerna
- Novel use of ultrasound-guided transgluteal sciatic nerve block to treat severe herpes zoster pain along the S1 dermatome
- Jeremiah J. Cross, Ali Zahir, David A. Martin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?